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Cruz et al. (2010) in their recent meta-analysis of eﬃ-
cacy of modern antipsychotics in bipolar depression
suggest that olanzapine and quetiapine demonstrate
eﬃcacy as monotherapy from week 1 onwards. They
claim that rapid onset is a particular feature with these
medications in this population. Both quetiapine and
olanzapine are known for their sedative eﬀects and
they also cause an increase in appetite. In addition,
being major tranquillizers, they have a calming
anxiolytic eﬀect. This can have impact on at least
three items on the MADRS – appetite, sleep and inner
tension. A minimal change on these three items can
cause a decrease of up to 6 points on the MADRS
(mean diﬀerence in change from baseline seen in
the BOLDER studies between the study drug and
placebo). This is signiﬁcant especially when we take
into account the fact that placebo response was found
to be quite high in the BOLDER and aripirazole
studies (mean change of almost 12 points on MADRS).
Although the BOLDER studies (Calabrese et al. 2005;
Thase et al. 2006) showed a decrease in core depressive
symptoms in addition to eﬀects on sleep and appetite,
eﬀects seen in Tohen et al.’s (2003) study were pri-
marily suggestive of a sedative, anxiolytic and appe-
tite stimulant eﬀect of the drug rather than eﬀects on
core depressive symptoms. The immediate onset of its
eﬀect (within a week) is also suggestive of the drug’s
action on sleep and appetite symptoms rather than
core depressive psychopathology. On the other hand,
aripiprazole is thought to cause less sedation, less
appetite stimulation, and possibly show less anxiolytic
activity. In fact, there were signiﬁcant numbers of ad-
verse eﬀects associated with insomnia, gastrointestinal
side-eﬀects and akathisia which accounted for a
signiﬁcant number of drop-outs in this population.
(Thase et al. 2008). This could account for the apparent
non-eﬃcacy of the drug. We suggest that results of
these studies should be interpreted with caution.
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